Nestedness and discontinuities in species-range-size distributions.

J. Kolasa

DOI: https://doi.org/10.1016/0169-5347(96)81151-7

IF: 20.589

1996-10-01

Trends in Ecology & Evolution

Abstract:

What problem does this paper attempt to address?

Juvenile-onset PSAT1-related neuropathy: A milder phenotype of serine deficiency disorder

Yu Shen,Yun Peng,Pengcheng Huang,Yilei Zheng,Shumeng Li,Kaiyan Jiang,Meihong Zhou,Jianwen Deng,Min Zhu,Daojun Hong

DOI: https://doi.org/10.3389/fgene.2022.949038

IF: 3.7

2022-08-16

Frontiers in Genetics

Abstract:Background: Primary serine deficiency disorders have a broad range of the phenotypic spectrum. As an inborn error of metabolism, individuals with severe phenotype may be easily recognized with Neu-Laxova syndrome. However, late-onset mild phenotypes may be underdiagnosed and will lead to disastrous consequences due to treatment delays. Materials and Methods: Clinical features of patients with serine deficiency disorders were summarized in two unrelated patients. Skin and sural nerve biopsies were conducted on the patients. Whole exome sequencing (WES) was performed in the index patients. Sanger sequencing was used to analyze family cosegregation. Results: Patient 1 was a 19-year-old male presenting with infancy-onset ichthyosis and juvenile-onset neuropathy. Patient 2 was a 17-year-old male manifesting childhood-onset ichthyosis and juvenile-onset neuropathy. Except for nystagmus, no other developmental or neurodegenerative disorders were found in the patients. Electrophysiological studies indicated a severe sensorimotor axonal neuropathy with a possible demyelinating component. High-dose oral L-serine and glycine completely alleviated skin lesions and only slightly improved neuropathy symptoms. Skin biopsies showed typical features consistent with ichthyosis and severe loss of unmyelinated axons. Sural biopsies revealed a severe loss of axons and a few thinly myelinated fibers. WES found the same homozygous variant c.43G > C ( p .A15P) in the PSAT1 gene, which was cosegregated in the two families. Conclusions: The skin and nervous system may be the main affected targets in serine deficiency disorders. Our patients show a more simple and mild phenotype of PSAT1 -related serine deficiency disorder. The pathological changes and regenerative ability of skin and peripheral nerves determine their response to serine supplements.

genetics & heredity
Phosphoserine aminotransferase deficiency diagnosed by whole‐exome sequencing and LC–MS/MS reanalysis: A case report and review of literature

Jiaci Li,Xinping Wei,Yuchen Sun,Xiaofang Chen,Ying Zhang,Xiaoyu Cui,Jianbo Shu,Dong Li,Chunquan Cai

DOI: https://doi.org/10.1002/mgg3.2400

2024-03-30

Molecular Genetics & Genomic Medicine

Abstract:We reported a 2‐year‐old female child with developmental delay, dyskinesia, and microcephaly. The patient was eventually diagnosed as PSATD by WES combined with LC–MS/MS reanalysis. This case provides a vital reference for the diagnosis of future genetic disease cases. Background Phosphoserine aminotransferase deficiency (PSATD) is an autosomal recessive disorder associated with hypertonia, psychomotor retardation, and acquired microcephaly. Patients with PSATD have low concentrations of serine in plasma and cerebrospinal fluid. Methods We reported a 2‐year‐old female child with developmental delay, dyskinesia, and microcephaly. LC–MS/MS was used to detect amino acid concentration in the blood and whole‐exome sequencing (WES) was used to identify the variants. PolyPhen‐2 web server and PyMol were used to predict the pathogenicity and changes in the 3D model molecular structure of protein caused by variants. Results WES demonstrated compound heterozygous variants in PSAT1, which is associated with PSATD, with a paternal likely pathogenic variant (c.235G>A, Gly79Arg) and a maternal likely pathogenic variant (c.43G>C, Ala15Pro). Reduced serine concentration in LC–MS/MS further confirmed the diagnosis of PSATD in this patient. Conclusions Our findings demonstrate the importance of WES combined with LC–MS/MS reanalysis in the diagnosis of genetic diseases and expand the PSAT1 variant spectrum in PSATD. Moreover, we summarize all the cases caused by PSAT1 variants in the literature. This case provides a vital reference for the diagnosis of future cases.

genetics & heredity
Expanding the genotypic and phenotypic spectrum of severe serine biosynthesis disorders

Fatima Abdelfattah,Ariana Kariminejad,Anne-Karin Kahlert,Patrick J Morrison,Evren Gumus,Katherine D Mathews,Benjamin W Darbro,David J Amor,Maie Walsh,Yves Sznajer,Luisa Weiß,Sabine Weidensee,David Chitayat,Patrick Shannon,Eva Bermejo-Sánchez,Isolina Riaño-Galán,Ian Hayes,Gemma Poke,Caroline Rooryck,Perrine Pennamen,Suonavy Khung-Savatovsky,Annick Toutain,Marie-Laure Vuillaume,Siavash Ghaderi-Sohi,Mohamad H Kariminejad,Sönke Weinert,Heinrich Sticht,Martin Zenker,Denny Schanze

DOI: https://doi.org/10.1002/humu.24067

Abstract:Serine biosynthesis disorders comprise a spectrum of very rare autosomal recessive inborn errors of metabolism with wide phenotypic variability. Neu-Laxova syndrome represents the most severe expression and is characterized by multiple congenital anomalies and pre- or perinatal lethality. Here, we present the mutation spectrum and a detailed phenotypic analysis in 15 unrelated families with severe types of serine biosynthesis disorders. We identified likely disease-causing variants in the PHGDH and PSAT1 genes, several of which have not been reported previously. Phenotype analysis and a comprehensive review of the literature corroborates the evidence that serine biosynthesis disorders represent a continuum with varying degrees of phenotypic expression and suggest that even gradual differences at the severe end of the spectrum may be correlated with particular genotypes. We postulate that the individual residual enzyme activity of mutant proteins is the major determinant of the phenotypic variability, but further functional studies are needed to explore effects at the enzyme protein level.
L-serine deficiency: on the properties of the Asn133Ser variant of human phosphoserine phosphatase

Loredano Pollegioni,Barbara Campanini,Jean-Marc Good,Zoraide Motta,Giulia Murtas,Valeria Buoli Comani,Despina-Christina Pavlidou,Noëlle Mercier,Laureane Mittaz-Crettol,Silvia Sacchi,Francesco Marchesani

DOI: https://doi.org/10.1038/s41598-024-63164-y

IF: 4.6

2024-05-31

Scientific Reports

Abstract:The non-essential amino acid L-serine is involved in a number of metabolic pathways and in the brain its level is largely due to the biosynthesis from the glycolytic intermediate D-3-phosphoglycerate by the phosphorylated pathway (PP). This cytosolic pathway is made by three enzymes proposed to generate a reversible metabolon named the "serinosome". Phosphoserine phosphatase (PSP) catalyses the last and irreversible step, representing the driving force pushing L-serine synthesis. Genetic defects of the PP enzymes result in strong neurological phenotypes. Recently, we identified the homozygous missense variant [NM_004577.4: c.398A > G p.(Asn133Ser)] in the PSPH , the PSP encoding gene, in two siblings with a neurodevelopmental syndrome and a myelopathy. The recombinant Asn133Ser enzyme does not show significant alterations in protein conformation and dimeric oligomerization state, as well as in enzymatic activity and functionality of the reconstructed PP. However, the Asn133Ser variant is less stable than wild-type PSP, a feature also apparent at cellular level. Studies on patients' fibroblasts also highlight a strong decrease in the level of the enzymes of the PP, a partial nuclear and perinuclear localization of variant PSP and a stronger perinuclear aggregates formation. We propose that these alterations contribute to the formation of a dysfunctional serinosome and thus to the observed reduction of L-serine, glycine and D-serine levels (the latter playing a crucial role in modulating NMDA receptors). The characterization of patients harbouring the Asn133Ser PSP substitution allows to go deep into the molecular mechanisms related to L-serine deficit and to suggest treatments to cope with the observed amino acids alterations.

multidisciplinary sciences
A yeast-based complementation assay elucidates the functional impact of 200 missense variants in human PSAT1

Amy Sirr,Russell S Lo,Gareth A Cromie,Adrian C Scott,Julee Ashmead,Mirutse Heyesus,Aimée M Dudley

DOI: https://doi.org/10.1002/jimd.12227

Abstract:Defects in serine biosynthesis resulting from loss of function mutations in PHGDH, PSAT1, and PSPH cause a set of rare, autosomal recessive diseases known as Neu-Laxova syndrome (NLS) or serine-deficiency disorders. The diseases present with a broad range of phenotypes including lethality, severe neurological manifestations, seizures, and intellectual disability. However, because L-serine supplementation, especially if started prenatally, can ameliorate and in some cases even prevent symptoms, knowledge of pathogenic variants is medically actionable. Here, we describe a functional assay that leverages the evolutionary conservation of an enzyme in the serine biosynthesis pathway, phosphoserine aminotransferase, and the ability of the human protein-coding sequence (PSAT1) to functionally replace its yeast ortholog (SER1). Results from our quantitative, yeast-based assay agree well with clinical annotations and expectations based on the disease literature. Using this assay, we have measured the functional impact of the 199 PSAT1 variants currently listed in ClinVar, gnomAD, and the literature. We anticipate that the assay could be used to comprehensively assess the functional impact of all SNP-accessible amino acid substitution mutations in PSAT1, a resource that could aid variant interpretation and identify potential NLS carriers.
Genome sequencing enables diagnosis and treatment of SLC5A6 neuropathy

Lisa G. Riley,Subrata Sabui,Hamid M. Said,Aram Niaz,Katta M. Girisha,Periyasamy Radhakrishnan,Sheela Nampoothiri,Dhanya Yesodharan,Tatjana Kilo,Janine Smith,Rachel S. H. Wong,Manoj P. Menezes,Sachin Gupta,Sandra T. Cooper,Shanti Balasubramaniam

DOI: https://doi.org/10.1038/s41431-024-01641-8

2024-05-31

European Journal of Human Genetics

Abstract:The sodium-dependent multivitamin transporter encoded by SLC5A6 is responsible for uptake of biotin, pantothenic acid, and α-lipoic acid. Thirteen individuals from eight families are reported with pathogenic biallelic SLC5A6 variants. Phenotype ranges from multisystem metabolic disorder to childhood-onset peripheral motor neuropathy. We report three additional affected individuals with biallelic SLC5A6 variants. In Family A, a male proband (AII:1) presenting in early childhood with gross motor regression, motor axonal neuropathy, recurrent cytopenia and infections, and failure to thrive was diagnosed at 12 years of age via genome sequencing (GS) with a paternal NM_021095.4:c.393+2T>C variant and a maternal c.1285A>G p.(Ser429Gly) variant. An uncle with recurrent cytopenia and peripheral neuropathy was subsequently found to have the same genotype. We also report an unrelated female with peripheral neuropathy homozygous for the c.1285A>G p.(Ser429Gly) recurrent variant identified in seven reported cases, including this study. RT-PCR studies on blood mRNA from AII:1 showed c.393+2T>C caused mis-splicing with all canonically spliced transcripts in AII:1 containing the c.1285A>G variant. SLC5A6 mRNA expression in AII:1 fibroblasts was ~50% of control levels, indicative of nonsense-mediated decay of mis-spliced transcripts. Biotin uptake studies on AII:1 fibroblasts, expressing the p.(Ser429Gly) variant, showed an ~90% reduction in uptake compared to controls. Targeted treatment of AII:1 with biotin, pantothenic acid, and lipoic acid resulted in clinical improvement. Health Economic analyses showed implementation of GS as an early investigation could have saved $ AUD 105,988 and shortened diagnostic odyssey and initiation of treatment by up to 7 years.

genetics & heredity,biochemistry & molecular biology
Case Report: A Compound Heterozygous Mutations in ASNS Broadens the Spectrum of Asparagine Synthetase Deficiency in the Prenatal Diagnosis

Linyan Zhu,Yixi Sun,Yuqing Xu,Pengzhen Jin,Huiqing Ding,Minyue Dong

DOI: https://doi.org/10.3389/fped.2023.1273789

IF: 3.569

2023-01-01

Frontiers in Pediatrics

Abstract:Asparagine synthetase deficiency (ASNSD) is a rare congenital disorder characterized by severe progressive microcephaly, global developmental delay, spastic quadriplegia, and refractory seizures. ASNSD is caused by variations of the ASNS gene. The present study showed a Chinese family with a fetus suffering microcephaly. Whole-exome sequencing and Sanger sequencing were used to identify the disease-associated genetic variants. Compound heterozygous variants c.97C>T p. (R33C) and c.1031-2_1033del were identified in the ASNS gene and the variants were inherited from the parents. The mutation site c.97C>T was highly conserved across a wide range of species and predicted to alter the local electrostatic potential. The variant c.1031-2_1033del was classified pathogenic. However, there is no case report of prenatal diagnosis of ASNSD. This is the first description of fetal compound mutations in the ASNS gene leading to ASNSD, which expanded the spectrum of ASNSD.
A report of a pedigree with compound heterozygous mutations in the SLC22A5 gene

Yunguo Zhou,Yucai Liu,Yang Shen,Fang Xu,Fei Xu,Hui Huang,Junkai Duan

DOI: https://doi.org/10.3389/fped.2023.985720

IF: 3.569

2023-06-06

Frontiers in Pediatrics

Abstract:Introduction: To investigate the clinical characteristics and disease outcomes of a pedigree with compound heterozygous mutations in the SLC22A5 gene. Methods: Serum acylcarnitine profiles of patients were analyzed using tandem mass spectrometry. DNA samples isolated from patients and their first-degree relatives were subjected to high-throughput sequencing, and mutations were validated using Sanger sequencing. Results: The proband, a 4-month-old girl, presented with seizure episodes and mild cardiac hypertrophy and was diagnosed with primary carnitine deficiency (PCD), with carnitine levels of 5.165 mol/L. Her brother, a 6-year-and 4-month-old boy, was also diagnosed with PCD with serum-free carnitine levels of 1.014 mol/L (reference values 10–60 mol/L). Compound heterozygous mutations (c.760C > T [p.R254X] and c.825G > A [p.W275X]) were detected in the SLC22A5 gene in both patients and were inherited from the mother and father, respectively. Oral L-carnitine significantly improved or resolved the clinical symptoms. Conclusion: Children with compound mutations in SLC22A5 may present different clinical manifestations, particularly at different ages. Early clinical manifestations have a greater impact on the organs and may cause irreversible damage. PCD can cause epilepsy and dilated cardiomyopathy. Tandem mass spectrometry and high-throughput sequencing are recommended to confirm the diagnosis. Early L-carnitine supplementation can improve symptoms and reverse organ damage in some children. Tandem mass spectrometry should be used to screen for newborns with a family history of PCD.

pediatrics
Succinic semialdehyde dehydrogenase deficiency: review of the clinical phenotype and metabolic/genomic approach to diagnosis

Kevin E. Glinton,Charul Gijavanekar,Abbhirami Rajagopal,Laura P. Mackay,Kirt A. Martin,Phillip L. Pearl,K. Michael Gibson,Theresa A. Wilson,V. Reid Sutton,Sarah H. Elsea

DOI: https://doi.org/10.3389/fgene.2024.1405468

IF: 3.7

2024-06-20

Frontiers in Genetics

Abstract:Genomic sequencing offers an untargeted, data-driven approach to genetic diagnosis; however, variants of uncertain significance often hinder the diagnostic process. The discovery of rare genomic variants without previously known functional evidence of pathogenicity often results in variants being overlooked as potentially causative, particularly in individuals with undifferentiated phenotypes. Consequently, many neurometabolic conditions, including those in the GABA (gamma-aminobutyric acid) catabolism pathway, are underdiagnosed. Succinic semialdehyde dehydrogenase deficiency (SSADHD, OMIM #271980) is a neurometabolic disorder in the GABA catabolism pathway. The disorder is due to bi-allelic pathogenic variants in ALDH5A1 and is usually characterized by moderate-to-severe developmental delays, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, psychiatric disorders, and sleep disturbances. In this study, we utilized an integrated approach to diagnosis of SSADHD by examining molecular, clinical, and metabolomic data from a single large commercial laboratory. Our analysis led to the identification of 16 patients with likely SSADHD along with three novel variants. We also showed that patients with this disorder have a clear metabolomic signature that, along with molecular and clinical findings, may allow for more rapid and efficient diagnosis. We further surveyed all available pathogenic/likely pathogenic variants and used this information to estimate the global prevalence of this disease. Taken together, our comprehensive analysis allows for a global approach to the diagnosis of SSADHD and provides a pathway to improved diagnosis and potential incorporation into newborn screening programs. Furthermore, early diagnosis facilitates referral to genetic counseling, family support, and access to targeted treatments–taken together, these provide the best outcomes for individuals living with either GABA-TD or SSADHD, as well as other rare conditions.

genetics & heredity
Successful use of canakinumab in a patient with resistant Behçet's disease.

L. Cantarini,A. Vitale,M. Borri,M. Galeazzi,R. Franceschini

2012-05-01

Clinical and Experimental Rheumatology

Abstract:
Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

Payam Mohassel,Sandra Donkervoort,Museer A. Lone,Matthew Nalls,Kenneth Gable,Sita D. Gupta,A. Reghan Foley,Ying Hu,Jonas Alex Morales Saute,Ana Lucila Moreira,Fernando Kok,Alessandro Introna,Giancarlo Logroscino,Christopher Grunseich,Alec R. Nickolls,Naemeh Pourshafie,Sarah B. Neuhaus,Dimah Saade,Andrea Gangfuß,Heike Kölbel,Zoe Piccus,Claire E. Le Pichon,Chiara Fiorillo,Cindy V. Ly,Ana Töpf,Lauren Brady,Sabine Specht,Aliza Zidell,Helio Pedro,Eric Mittelmann,Florian P. Thomas,Katherine R. Chao,Chamindra G. Konersman,Megan T. Cho,Tracy Brandt,Volker Straub,Anne M. Connolly,Ulrike Schara,Andreas Roos,Mark Tarnopolsky,Ahmet Höke,Robert H. Brown,Chia-Hsueh Lee,Thorsten Hornemann,Teresa M. Dunn,Carsten G. Bönnemann

DOI: https://doi.org/10.1038/s41591-021-01346-1

IF: 82.9

2021-05-31

Nature Medicine

Abstract:Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease of the lower and upper motor neurons with sporadic or hereditary occurrence. Age of onset, pattern of motor neuron degeneration and disease progression vary widely among individuals with ALS. Various cellular processes may drive ALS pathomechanisms, but a monogenic direct metabolic disturbance has not been causally linked to ALS. Here we show SPTLC1 variants that result in unrestrained sphingoid base synthesis cause a monogenic form of ALS. We identified four specific, dominantly acting SPTLC1 variants in seven families manifesting as childhood-onset ALS. These variants disrupt the normal homeostatic regulation of serine palmitoyltransferase (SPT) by ORMDL proteins, resulting in unregulated SPT activity and elevated levels of canonical SPT products. Notably, this is in contrast with SPTLC1 variants that shift SPT amino acid usage from serine to alanine, result in elevated levels of deoxysphingolipids and manifest with the alternate phenotype of hereditary sensory and autonomic neuropathy. We custom designed small interfering RNAs that selectively target the SPTLC1 ALS allele for degradation, leave the normal allele intact and normalize sphingolipid levels in vitro. The role of primary metabolic disturbances in ALS has been elusive; this study defines excess sphingolipid biosynthesis as a fundamental metabolic mechanism for motor neuron disease.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Hepatitis C virus (HCV) therapies special thematic issue: call for papers.

Gunda Ingrid Georg,Shaomeng Wang

DOI: https://doi.org/10.1021/jm301895h

IF: 8.039

2013-01-07

Journal of Medicinal Chemistry

Abstract:
A new type of blood–brain barrier aminoacidopathy underlies metabolic microcephaly associated with SLC1A4 mutations

Maali Odeh,Clara Sajrawi,Adam Majcher,Salman Zubedat,Lihi Shaulov,Alex Radzishevsky,Liron Mizrahi,Wendy K Chung,Avi Avital,Thorsten Hornemann,Daniel J Liebl,Inna Radzishevsky,Herman Wolosker

DOI: https://doi.org/10.1093/brain/awae134

IF: 14.5

2024-04-26

Brain

Abstract:Mutations in the SLC1A4 transporter lead to neurodevelopmental impairments, spastic tetraplegia, thin corpus callosum, and microcephaly in children. SLC1A4 catalyzes obligatory amino acid exchange between neutral amino acids, but the physiopathology of SLC1A4 disease mutations and progressive microcephaly remain unclear. Here, we examined the phenotype and metabolic profile of three Slc1a4 mouse models, including a constitutive Slc1a4-KO mouse, a knock-in mouse with the major human Slc1a4 mutation (Slc1a4-K256E), and a selective knockout of Slc1a4 in brain endothelial cells (Slc1a4tie2-cre). We show that Slc1a4 is a bona fide L-serine transporter at the BBB and that acute inhibition or deletion of Slc1a4 leads to a decrease in serine influx into the brain. This results in microcephaly associated with decreased L-serine content in the brain, accumulation of atypical and cytotoxic 1-deoxysphingolipids in the brain, neurodegeneration, synaptic and mitochondrial abnormalities, and behavioral impairments. Prenatal and early postnatal oral administration of L-serine at levels that replenish the serine pool in the brain rescued the observed biochemical and behavioral changes. Administration of L-serine till the second postnatal week also normalized brain weight in Slc1a4-E256 K mice. Our observations suggest that the transport of "non-essential" amino acids from the blood through the BBB is at least as important as that of essential amino acids for brain metabolism and development. We proposed that SLC1A4 mutations cause a BBB aminoacidopathy with deficits in serine import across the BBB required for optimal brain growth and leads to a metabolic microcephaly, which may be amenable to treatment with L-serine.

neurosciences,clinical neurology
SERAC1 Deficiency- A New Phenotype.

João Durães,Emanuel Martins,João Gomes,Carmo Macário,C. Nogueira,L. Vilarinho

DOI: https://doi.org/10.2174/1871530323666230914114456

2023-09-14

Abstract:Introduction - SERAC1 deficiency phenotype range from MEGD(H)EL syndrome, the most severe, to juvenile complicated spastic paraplegia, to adult-onset dystonic features (in only one patient). The MEGD(H)EL syndrome is characterized by (3-methylglutaconic aciduria with deafness-dystonia, [hepatopathy], encephalopathy, and Leigh-like syndrome). Biochemical abnormalities: elevated urinary 3 - metilglutaconic and 3-metilglutaric acids, high lactate and alanine in serum. Diagnosis is confirmed when biallelic pathogenic variants in SERAC1 gene are found. Brain MRI: basal ganglia lesions and generalized atrophy. Results/Case report - A 30-year-old patient with a moderate intellectual disability, developed, since the age of 25, a progressive loss of previous capacities (hand dexterity, oral language), and later subacute generalized dystonic features. Currently he has spastic tetraparesis, dystonia, scoliosis and autistic behavior, with bilateral basal ganglia lesions on brain MRI. Genetic study revealed biallelic pathogenic variants in SERAC1 gene, confirm MEGD(H)EL. A 73 years old patient with cognitive impairment and progressive spastic tetraparesis had multiple periventricular T2 hyperintense lesions. She has a homozygotic SERAC1 variant NM_032861: exon4:c.T139A: p.F471 (rs112780453), considered benign. Biochemical study revealed elevated plasmatic alanine and urinary3-metilglutaconic and 3-metilglutaric acid. This profile is concordant with mitochondrial dysfunction and SERAC1 Deficit. Conclusion - The first patient has the clinical symptoms associated to the MEGD(H)EL syndrome, and the biochemical and genetic confirmation of the diagnosis, without reservations. However, in the second patient, the progressive paraparesis and cognitive impairment did not appear to be caused by multiple sclerosis nor subcortical vascular leukoencephalopathy (without vascular risk factors). The abnormal biochemical profile is suggestive of SERAC1 Deficiency, even without genetic confirmation. In what should we believe?

Medicine
[The University Hospital of Children Queen Fabiola and the Bordet Institute, two jewels of academic research].

J. Frühling

Revue Medicale de Bruxelles

Abstract:
The use of hormones in reproductive management of the mare.

J. P. Hughes,G. Stabenfeldt

DOI: https://doi.org/10.1111/J.1751-0813.1977.TB00210.X

1977-06-01

Australian Veterinary Journal

Abstract:A brief review is presented of the use in equine veterinary medicine of anterior pituitary hormones, posterior pituitary hormones, placental hormones, steroid hormones and prostaglandins. These hormones are used frequently in clinical application without a scientific basis for their expected activity.
Managed care: form, function, and evolution.

S. Gottlieb,T. Einhorn

DOI: https://doi.org/10.2106/00004623-199701000-00015

Abstract:During the last decade, health care in the United States has become a cost-conscious and, in some instances, a cost-driven industry. To a large measure, this focus on price explains the reasons behind the phenomenal growth of managed-care companies in the last ten years. These arrangements are now an integral component of the nation's health-care-delivery system, and many experienced observers believe that they have the potential to reduce or eliminate much of the inefficiency in the current system. Health-care plans such as those offered by health-maintenance organizations (HMOs) are thought to provide comprehensive coverage for enrollees at a lower cost than is associated with the episodic care that people receive under traditional indemnity policies. An HMO delivers comprehensive, coordinated medical services to voluntarily enrolled members on a prepaid basis. The risks and costs are frequently borne by the provider (the independent clinical professionals and institutions that furnish services to the consumer). As the HMO is obligated to provide all medically necessary care to its enrollees, it is thought to have a direct incentive for making sure that its members remain healthy. Managed care has been greeted by many legislators, business leaders, and health-policy experts as a promising alternative to traditional indemnity health coverage. Since 1973, employers who are self-insured—typically, large corporations—have been required by federal law to include an HMO as part of any list of options for health-care coverage that they offer to their employees. Starting in the 1970's with non-profit plans such as those offered by Kaiser-Permanente of California, the industry expanded rapidly and, by the 1980's, many for-profit programs were in operation. With the for-profit models available, the private-insurance sector that once avoided controlling services moved far in the direction of managed care, sometimes blurring the distinction between traditional insurance providers and managed-care plans. More than fifty …
De novo missense variants in exon 9 of SEPHS1 cause a neurodevelopmental condition with developmental delay, poor growth, hypotonia, and dysmorphic features

Sureni V. Mullegama,Kaitlyn A. Kiernan,Erin Torti,Ethan Pavlovsky,Nicholas Tilton,Austin Sekula,Hua Gao,Joseph T. Alaimo,Kendra Engleman,Eric T. Rush,Karli Blocker,Katrina M. Dipple,Veronica M. Fettig,Heather Hare,Ian Glass,Dorothy K. Grange,Michael Griffin,Chanika Phornphutkul,Lauren Massingham,Lakshmi Mehta,Danny E. Miller,Jenny Thies,J Lawrence Merritt,Eric Muller,Matthew Osmond,Sarah L. Sawyer,Rachel Slaugh,Rachel E. Hickey,Barry Wolf,Sanjeev Choudhary,Miljan Simonović,Yueqing Zhang,Timothy Blake Palculict,Aida Telegrafi,Deanna Alexis Carere,Ingrid M. Wentzensen,Michelle M. Morrow,Kristin G. Monaghan,Jun Yang,Jane Juusola

DOI: https://doi.org/10.1016/j.ajhg.2024.02.016

2024-04-05

The American Journal of Human Genetics

Abstract:SEPHS1 is in the selenocysteine biosynthetic pathway. We report nine individuals from eight families with developmental delay, growth and feeding problems, hypotonia, and dysmorphic features, all with heterozygous missense variants in SEPHS1. Our findings provide insight into the molecular pathogenesis of this neurodevelopmental disorder.

genetics & heredity
Hereditary tumour syndromes featuring basal cell carcinomas

Lizelotte J. M. T. Parren,J. Frank

DOI: https://doi.org/10.1111/j.1365-2133.2011.10334.x

IF: 11.113

2011-07-01

British Journal of Dermatology

Abstract:Basal cell carcinoma (BCC) is the most frequent cutaneous malignancy worldwide. This skin tumour is characterized by a broad phenotypic variability and distinct histopathological subtypes. It shows slow, locally invasive growth and only rarely metastasizes. BCCs can occur either sporadically or in the context of genetic syndromes, including Gorlin syndrome, Bazex–Dupré–Christol syndrome, Rombo syndrome, Oley syndrome and xeroderma pigmentosum. Different genes and signalling routes have been shown to play an important role in the development and growth of these tumours, including the hedgehog and Wnt/β‐catenin pathway. In some of the aforementioned hereditary disorders the underlying genetic defect is still unknown whereas in others several genes have been demonstrated to be involved. Currently, most therapeutic approaches are based on surgical measures. In the case of superficial BCCs, photodynamic therapy, 5‐fluorouracil cream, imiquimod or radiotherapy also may be an option. Elucidation of the molecular mechanisms governing the manifestation of BCCs in monogenetically inherited tumour syndromes will not only contribute to a better understanding of the complex pathogenesis of these tumours but might pave the way to the development of noninvasive, specific and molecule‐based therapeutic strategies in the near future.
Resolution of SLC6A1 variable expressivity in a multi-generational family using deep clinical phenotyping and Drosophila models

Kristy Jay,Nikhita Gogate,Kim Ezell,Jonathan Andrews,Sharayu Jangam,Paige Hall,Hongling Pan,Kelvin Pham,Ryan German,Vanessa Gomez,Emily Jellinek-Russo,Eric Storch,SHINYA YAMAMOTO,Oguz Kanca,Hugo J Bellen,Herman Dierick,Joy Cogan,John A Phillips,Rizwan Hamid,Thomas Cassini,Lynette Rives,Jennifer E Posey,Michael F Wangler

DOI: https://doi.org/10.1101/2024.09.27.24314092

2024-09-28

Abstract:Variants of uncertain significance pose a difficult diagnostic and therapeutic problem, even when the candidate gene has previously been associated with Mendelian disease. Variants in SLC6A1 result in a rare neurodevelopmental disorder characterized by a variable clinical presentation of symptoms including developmental delay, epilepsy, motor dysfunction, and autism spectrum disorder. SLC6A1 encodes the γ-aminobutyric acid (GABA) transporter (GAT-1) protein that is responsible for the reuptake of GABA from the synapse to maintain homeostasis of excitatory and inhibitory neurotransmitters. SLC6A1 haploinsufficiency has been confirmed as the predominant pathway of SLC6A1-related neurodevelopmental disorders, however, the molecular mechanism underlying the variable presentation of clinical features remains unclear. Here, through work of the Undiagnosed Diseases Network, we identify an undiagnosed individual with an inherited p.(A334S) variant of uncertain significance. Pedigree analysis identifies variable symptoms between family members with the same variant. To resolve this case, we first compare proband phenotypes to a cohort of cases diagnosed with SLC6A1-related neurodevelopmental disorders and find significant symptom overlap. We then functionally compare this variant to other variants by creating an allelic series in the fruit fly Drosophila melanogaster. We identify phenotypes in flies expressing SLC6A1 variants consistent with a loss-of-function mechanism and conclude that the p.(A334S) variant is a hypomorphic allele. Through clinical and functional genomics, we begin to elucidate the underlying variability in SLC6A1-neurodevelopmental disorders. These insights will inform clinical diagnosis, prognosis, treatment planning, and aid in the design of targeted therapeutics for those living with SLC6A1-related neurodevelopmental disorders.

Genetic and Genomic Medicine

Nestedness and discontinuities in species-range-size distributions.

Juvenile-onset PSAT1-related neuropathy: A milder phenotype of serine deficiency disorder

Phosphoserine aminotransferase deficiency diagnosed by whole‐exome sequencing and LC–MS/MS reanalysis: A case report and review of literature

Expanding the genotypic and phenotypic spectrum of severe serine biosynthesis disorders

L-serine deficiency: on the properties of the Asn133Ser variant of human phosphoserine phosphatase

A yeast-based complementation assay elucidates the functional impact of 200 missense variants in human PSAT1

Genome sequencing enables diagnosis and treatment of SLC5A6 neuropathy

Case Report: A Compound Heterozygous Mutations in ASNS Broadens the Spectrum of Asparagine Synthetase Deficiency in the Prenatal Diagnosis

A report of a pedigree with compound heterozygous mutations in the SLC22A5 gene

Succinic semialdehyde dehydrogenase deficiency: review of the clinical phenotype and metabolic/genomic approach to diagnosis

Successful use of canakinumab in a patient with resistant Behçet's disease.

Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

Hepatitis C virus (HCV) therapies special thematic issue: call for papers.

A new type of blood–brain barrier aminoacidopathy underlies metabolic microcephaly associated with SLC1A4 mutations

SERAC1 Deficiency- A New Phenotype.

[The University Hospital of Children Queen Fabiola and the Bordet Institute, two jewels of academic research].

The use of hormones in reproductive management of the mare.

Managed care: form, function, and evolution.

De novo missense variants in exon 9 of SEPHS1 cause a neurodevelopmental condition with developmental delay, poor growth, hypotonia, and dysmorphic features

Hereditary tumour syndromes featuring basal cell carcinomas

Resolution of SLC6A1 variable expressivity in a multi-generational family using deep clinical phenotyping and Drosophila models